Cargando…

Accurate expression of PD‐L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry

The percentage of programmed death ligand 1 (PD‐L1) positivity in cancer cells, named as the tumor proportion score, is considered to be a predictive biomarker for anti‐PD‐1/PD‐L1 therapy in lung cancer. PD‐L1 is expressed on not only cancer cells but also on immune cells, including macrophages. Alt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shinchi, Yusuke, Komohara, Yoshihiro, Yonemitsu, Kimihiro, Sato, Kensaku, Ohnishi, Koji, Saito, Yoichi, Fujiwara, Yukio, Mori, Takeshi, Shiraishi, Kenji, Ikeda, Koei, Suzuki, Makoto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6726681/ https://www.ncbi.nlm.nih.gov/pubmed/31294893 http://dx.doi.org/10.1111/cas.14128

Ejemplares similares

The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma
por: Shinchi, Yusuke, et al.
Publicado: (2022)

Classification of PD‐L1 expression in various cancers and macrophages based on immunohistocytological analysis
por: Saito, Yoichi, et al.
Publicado: (2022)

GM-CSF derived from the inflammatory microenvironment potentially enhanced PD-L1 expression on tumor-associated macrophages in human breast cancer
por: Yonemitsu, Kimihiro, et al.
Publicado: (2022)

PD-L1 expression in regional lymph nodes and predictable roles in anti-cancer immune responses
por: Komohara, Yoshihiro, et al.
Publicado: (2020)

CD163 deficiency facilitates lipopolysaccharide‐induced inflammatory responses and endotoxin shock in mice
por: Fujiwara, Yukio, et al.
Publicado: (2020)

SPP1 Derived from Macrophages Is Associated with a Worse Clinical Course and Chemo-Resistance in Lung Adenocarcinoma
por: Matsubara, Eri, et al.
Publicado: (2022)

An IL‐27/Stat3 axis induces expression of programmed cell death 1 ligands (PD‐L1/2) on infiltrating macrophages in lymphoma
por: Horlad, Hasita, et al.
Publicado: (2016)

CD169 (+) sinus macrophages in regional lymph nodes do not predict mismatch‐repair status of patients with colorectal cancer
por: Saito, Yoichi, et al.
Publicado: (2023)

Standardization of PD-L1 immunohistochemistry
por: Martinez-Morilla, Sandra, et al.
Publicado: (2021)

Synchronous Multiple Lung Adenocarcinomas: Estrogen Concentration in Peripheral Lung
por: Ikeda, Koei, et al.
Publicado: (2016)

Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy
por: Hu, Weixian
Publicado: (2019)

The Significance of SPP1 in Lung Cancers and Its Impact as a Marker for Protumor Tumor-Associated Macrophages
por: Matsubara, Eri, et al.
Publicado: (2023)

PD-L1 testing by immunohistochemistry in immuno-oncology
por: Vranic, Semir, et al.
Publicado: (2023)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer
por: Sharma, Meenal, et al.
Publicado: (2019)

Flavonoid Compounds Contained in Epimedii Herba Inhibit Tumor Progression by Suppressing STAT3 Activation in the Tumor Microenvironment
por: Pan, Cheng, et al.
Publicado: (2020)

PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC
por: Wu, Chiao-En, et al.
Publicado: (2020)

Guanylate-binding protein 5 is a marker of interferon-γ-induced classically activated macrophages
por: Fujiwara, Yukio, et al.
Publicado: (2016)

Maf expression in human macrophages and lymph node sinus macrophages in patients with esophageal cancer
por: Takeya, Hiroto, et al.
Publicado: (2019)

PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma
por: Maekawa, Naoya, et al.
Publicado: (2021)

Can PD-L1 expression evaluated by biopsy sample accurately reflect its expression in the whole tumour in gastric cancer?
por: Yamashita, Kohei, et al.
Publicado: (2019)

Aging-associated and CD4 T-cell–dependent ectopic CXCL13 activation predisposes to anti–PD-1 therapy-induced adverse events
por: Tsukamoto, Hirotake, et al.
Publicado: (2022)

A Novel Strategy for Inducing the Antitumor Effects of Triterpenoid Compounds: Blocking the Protumoral Functions of Tumor-Associated Macrophages via STAT3 Inhibition
por: Fujiwara, Yukio, et al.
Publicado: (2014)

Cholesterol metabolism and lipid droplet vacuoles; a potential target for the therapy of aggressive lymphoma
por: Yano, Hiromu, et al.
Publicado: (2022)

Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms
por: Ilie, Marius, et al.
Publicado: (2017)

“Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy
por: Torlakovic, Emina, et al.
Publicado: (2019)

Development and applications of computer image analysis algorithms for scoring of PD-L1 immunohistochemistry
por: Inge, L.J., et al.
Publicado: (2020)

Onionin A inhibits ovarian cancer progression by suppressing cancer cell proliferation and the protumour function of macrophages
por: Tsuboki, Junko, et al.
Publicado: (2016)

PD‐L1 and PD‐L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma
por: Okadome, Kazuo, et al.
Publicado: (2021)

Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers
por: Okadome, Kazuo, et al.
Publicado: (2020)

Possible functions of CD169‐positive sinus macrophages in lymph nodes in anti‐tumor immune responses
por: Komohara, Yoshihiro, et al.
Publicado: (2017)

Correction: Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms
por: Ilie, Marius, et al.
Publicado: (2017)

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab
por: Vennapusa, Bharathi, et al.
Publicado: (2019)

Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy
por: Yeong, Joe, et al.
Publicado: (2022)

PD-L1 expression in papillary renal cell carcinoma
por: Motoshima, Takanobu, et al.
Publicado: (2017)

Alginates as food ingredients absorb extra salt in sodium chloride-treated mice
por: Fujiwara, Yukio, et al.
Publicado: (2021)

Corosolic acid enhances the antitumor effects of chemotherapy on epithelial ovarian cancer by inhibiting signal transducer and activator of transcription 3 signaling
por: FUJIWARA, YUKIO, et al.
Publicado: (2013)

Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer
por: Phillips, Therese, et al.
Publicado: (2015)

Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors
por: Maekawa, Naoya, et al.
Publicado: (2023)

Harmonization across programmed death ligand 1 (PD‐L1) assays for lung cancer by immunohistochemistry using noncontact alternating current electric field mixing
por: Matsuo, Tsubasa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3bjcf4gfqr7rjvj3tt0c7irner